How big is Alkermes Plc?

As of Jun 18, Alkermes Plc has a market capitalization of 5,020.84 million, with net sales of 1,513.77 million and a net profit of 355.66 million over the latest four quarters.

Market Cap: As of Jun 18, Alkermes Plc has a market capitalization of 5,020.84 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Alkermes Plc reported net sales of 1,513.77 million and a net profit of 355.66 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,464.98 million and total assets of 2,055.57 million.

What does Alkermes Plc do?

Alkermes Plc is a mid-cap biopharmaceutical company focused on researching, developing, and commercializing pharmaceutical products. As of March 2025, it reported net sales of $307 million and a net profit of $22 million.

Overview:<BR>Alkermes Plc is a biopharmaceutical company engaged in researching, developing, and commercializing pharmaceutical products in the Pharmaceuticals & Biotechnology industry, with a market cap in the mid-cap bracket.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 307 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 22 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 5,020.84 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.58 <BR>Return on Equity: 23.57% <BR>Price to Book: 3.32<BR><BR>Contact Details:<BR>Address: Connaught HSE, 1 Burlington Road, DUBLIN None: 00000 <BR>Tel: 353 1 7728000 <BR>Website: http://www.alkermes.com

Who are in the management team of Alkermes Plc?

As of March 2022, the management team of Alkermes Plc includes CEO Richard Pops, Lead Independent Director David Anstice, and independent directors Shane Cooke, Robert Breyer, David Daglio, and Wendy Dixon.

As of March 2022, the management team of Alkermes Plc includes the following individuals:<BR><BR>- Mr. Richard Pops, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. David Anstice, who is the Lead Independent Director.<BR>- Mr. Shane Cooke, who is a Director.<BR>- Mr. Robert Breyer, who is an Independent Director.<BR>- Mr. David Daglio, who is also an Independent Director.<BR>- Dr. Wendy Dixon, who serves as an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive and independent directors, with Mr. Richard Pops at the helm as CEO.

Should I buy, sell or hold Alkermes Plc?

Is Alkermes Plc overvalued or undervalued?

As of July 7, 2025, Alkermes Plc is considered undervalued with a P/E ratio of 15 and favorable EV multiples compared to peers, despite a year-to-date return of -0.73% and a solid 3-year return of 31.42%, which lags behind the S&P 500's performance.

As of 7 July 2025, Alkermes Plc's valuation grade has moved from expensive to attractive, indicating a shift towards being undervalued. The company appears to be undervalued with a P/E ratio of 15, an EV to EBIT of 11.43, and an EV to EBITDA of 10.67, which are relatively favorable compared to its peers. For instance, Neurocrine Biosciences, Inc. has a significantly higher P/E ratio of 37.08, while Exelixis, Inc. shows an EV to EBITDA of 11.97, suggesting that Alkermes is more attractively priced within the industry.<BR><BR>Despite a year-to-date return of -0.73% compared to the S&P 500's 12.22%, Alkermes has shown a solid 3-year return of 31.42%, although it still lags behind the benchmark's 70.41%. This mixed performance reinforces the notion that while the stock may be undervalued, it has not kept pace with broader market gains recently.

Is Alkermes Plc technically bullish or bearish?

As of October 24, 2025, Alkermes Plc's technical outlook is mildly bearish, indicated by daily moving averages and monthly MACD, despite some bullish signals from the weekly MACD and Bollinger Bands.

As of 24 October 2025, the technical trend for Alkermes Plc has changed from mildly bullish to mildly bearish. The weekly MACD is bullish, while the monthly MACD is mildly bearish. The daily moving averages indicate a mildly bearish stance. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. The KST is bullish monthly but mildly bullish weekly, and Dow Theory reflects a mildly bearish weekly outlook against a mildly bullish monthly perspective. The OBV is mildly bearish in both weekly and monthly assessments. <BR><BR>In terms of performance, Alkermes has underperformed the S&P 500 over the past week and year-to-date, but has shown stronger returns over the past month and three years. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.